Select region:

Clinical trials located in

Manchester

Manchester city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Manchester, located in the northwest of England, is renowned for its significant role in the Industrial Revolution, earning it the nickname “Cottonopolis” due to its plethora of cotton mills. This city is also celebrated for its vibrant music scene, having birthed legendary bands like The Smiths and Oasis. Manchester boasts two Premier League football teams, Manchester United and Manchester City, highlighting its deep-rooted sports culture. Additionally, it is home to the University of Manchester, a member of the prestigious Russell Group, known for its research achievements, including the isolation of graphene.

  • CT-EU-00114182

    Evaluating the Impact of Management Approaches on Congenital Adrenal Hyperplasia Outcomes

    We are conducting a study at the Royal Manchester Children’s Hospital (RMCH) to understand the long-term effects of different treatments for Congenital Adrenal Hyperplasia (CAH), a condition that can affect genital appearance from birth. This research is especially focused on women and young girls who have this condition, as well as their parents. Our goal is to gather insights on how treatments, including surgery, have impacted their lives in various aspects such as socially, physically, emotionally, and sexually.

    The study is unique because it looks into the outcomes of both conservative (non-surgical) and surgical management of CAH over the last 50 years. We are particularly interested in how these treatments have affected genital appearance and overall quality of life. Moreover, we are exploring the perspectives of individuals and their parents on the idea of postponing early childhood surgery until the patient is old enough to participate in the decision-making process.

    Participation involves filling out questionnaires designed to capture your experiences and satisfaction with the treatment you or your child received. This study is crucial as it will help inform future treatment guidelines and support decision-making processes for families and healthcare providers dealing with CAH.

    Your contribution could also influence policy decisions and improve consultation practices with affected families. If you are an individual affected by CAH or a parent of a child with CAH, and you’ve been treated at RMCH, we invite you to share your story through our study-specific questionnaires. This research will run for 12 months, aiming to make a significant impact on the management of CAH.

    United Kingdom
  • Exploring the Impact of ATL1102 in Boys with Duchenne Muscular Dystrophy

    This study is designed to test the effectiveness and safety of a new treatment called ATL1102. The trial is specifically for boys aged 10 to <18 who cannot walk (non-ambulatory).

    The study is divided into two main parts. In the first part, participants will be randomly assigned to receive either ATL1102 at doses of 25 mg or 50 mg, or a placebo (a treatment with no active drug), given as a weekly subcutaneous injection. This phase will last for 24 weeks and is double-blind, meaning neither the participants nor the researchers will know who is receiving the actual drug or the placebo.

    Following this, all participants will move into the second part of the study, where they will receive ATL1102 for another 24 weeks. This part is open-label, which means everyone will know they are receiving the active drug.

    The main goal of the study is to see how well ATL1102 can improve upper limb strength, which is crucial for daily activities. This will be measured using the Performance of Upper Limb (PUL) 2.0 score, a tool designed to assess upper limb strength in individuals with DMD.

    BulgariaUnited Kingdom
  • Sparsentan Treatment Study for Children with Kidney Diseases

    We are excited to introduce a clinical trial focused on the study of Sparsentan treatment in children and adolescents with certain types of kidney diseases that lead to protein loss in urine, known as proteinuric glomerular diseases. This includes conditions like Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), Immunoglobulin A Nephropathy (IgAN), IgA Vasculitis (IgAV), and Alport Syndrome (AS).

    The main goal of this study is to understand how safe, effective, and tolerable Sparsentan is when given as an oral suspension or tablet. We are particularly interested in seeing how this treatment can change the levels of protein in the urine over a period of 108 weeks.

    This study is designed as a Phase 2, Open-Label, Single-Arm trial, meaning all participants will receive the treatment, and there will not be a comparison group receiving a placebo. We are looking to enroll approximately 67 pediatric subjects, aged 1 year to less than 18 years, who have been diagnosed with one of the specified conditions. The study is divided into three populations based on the specific disease and age groups, with different dosages of Sparsentan being tested across these groups.

    The safety of the participants will be closely monitored throughout the study, with a special focus on any treatment-emergent adverse events, serious adverse events, and any adverse events that may lead to discontinuation of the treatment. Additionally, we will measure the change in the urine protein/creatinine ratio (UP/C) from the start of the study to week 108 to assess the effectiveness of Sparsentan in reducing proteinuria.

    This study represents an important step towards finding a potentially effective treatment for children and adolescents suffering from these challenging kidney diseases. If you or your child are dealing with one of these conditions and are interested in participating, we encourage you to consider this unique opportunity.

    GermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Evaluating new medication in Congenital Hyperinsulinism treatment

    This clinical trial is focused on testing a new treatment called HM15136 for individuals aged 2 years and older who have Congenital Hyperinsulinism (CHI). CHI is a condition that causes persistent low blood sugar levels due to excessive insulin production. The study aims to find out how safe and effective HM15136 is when used alongside standard treatments that participants are already receiving for CHI.

    HM15136 will be given as a subcutaneous (under the skin) injection once a week for 8 weeks. The trial will look into how well the body tolerates this medication, any side effects that might occur, and how the body processes the drug. Additionally, the study will assess the effectiveness of HM15136 in managing blood sugar levels in participants.

    The safety of the participants will be closely monitored throughout the study, focusing on any adverse events, serious adverse events, and changes in clinical laboratory tests. The trial will also measure the highest concentration of the drug in the bloodstream and how long it takes to reach this peak level after administration.

    This study is an opportunity for individuals with CHI to potentially improve their condition and contribute to medical research in finding new treatments for this rare disease.

    GermanyUnited Kingdom
  • Clinical Study on Growth and Health in Children with Achondroplasia

    This is a long-term, multi-center, observational study for children aged 2.5 to <17 years who have been diagnosed with achondroplasia. The main objective of the study is to evaluate various aspects of the condition, including growth, medical complications related to achondroplasia, health-related quality of life, body pain, functional abilities, cognitive functions, and treatments received by the participants. The study will monitor changes in height Z score and upper to lower body segment ratio over a period of up to 2 years. No study medication will be administered to the participants during this observational study.

    FranceGermanyItalyNorwaySpainUnited Kingdom
  • CT-EU-00091440

    Investigating new drug, JNJ-75276617 for the treatment of patients with acute leukemia

    This study is about a new medicine called JNJ-75276617, designed to help patients with a type of blood cancer called Acute Leukemia. Acute leukemia is an illness where the bone marrow makes too many white blood cells that are abnormal. This study is divided into two parts: first, to figure out the best dose of the new medicine, and second, to check if it’s safe at that dose. For up to 2 years and 10 months, researchers will follow participants closely and check for any changes in their health. They will look at the number of participants who experience bad side effects, how much of the drug is in their bodies, and how the disease is responding to the new medicine. The main goal is to find a dose of the drug that’s both safe and can possibly help patients with acute leukemia.

  • CT-EU-00091315

    Testing infigratinib in children aged 3 to 11 years with achondroplasia

    This study focuses on evaluating the medication Infigratinib in young children aged 3 to 11 diagnosed with Achondroplasia who previously participated in the PROPEL study for at least 6 months. The primary objectives of this study are to assess the safety profile of Infigratinib in this specific age group, evaluate the children’s tolerance to potential side effects, and investigate the therapeutic efficacy of the medication for treating Achondroplasia. During the study, doses of Infigratinib will be incrementally increased to determine the optimal and most effective dosage for the participants.

  • Testing a new drug for advanced prostate cancer

    This trial compares a new drug called AZD5305 with a placebo in men who have a specific kind of prostate cancer that has not responded to usual treatment methods. It’s a large trial, with around 1800 participants, and the main aim is to see whether the new treatment can help slow down the disease for longer than current treatments. Participants will be assigned to two different groups, and they will not know whether they’re receiving the real drug or the placebo. Their health will be monitored closely, with regular scans to check the progress of the cancer. The trial will also look at any side effects of the treatment and how it affects the patients’ ability to do their daily activities.

    AustriaBelgiumFinlandFranceGermanyHungaryItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Research to enhance cancer treatments for kids and teens

    This clinical trial, known as CAMPFIRE, encompasses several studies testing new drugs for children and young adults with cancer. It includes various drug combinations such as Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel, Abemaciclib, Irinotecan, and Temozolomide. These trials aim to evaluate the safety and effectiveness of these drugs in treating different cancer types. The study is interventional, with an estimated enrollment of 105 participants, randomized in parallel assignment. The primary purpose is treatment-focused.

    BelgiumFranceGermanyItalyNetherlandsSpainUnited Kingdom
  • Studying rilzabrutinib for chronic immune thrombocytopenia

    The research is underway to evaluate the efficacy and safety of a medication called rilzabrutinib in adults and teenagers with Immune Thrombocytopenia (ITP), a chronic blood condition characterized by a low platelet count. Participants will receive either the medication or a placebo twice daily over a period of about a year and a half. Platelet levels, overall health, and quality of life will be measured before and during the study to gather comprehensive data.

    AustriaFranceGermanyHungaryItalyNetherlandsNorwayPolandSpainUnited Kingdom
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    BelgiumCzechiaFranceGreeceHungaryNetherlandsPolandSpainUnited Kingdom
  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    BelgiumFranceHungaryItalyPolandPortugalRomaniaSpainUnited Kingdom
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    AustriaBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    AustriaGermanySpainUnited Kingdom
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    AustriaBelgiumFranceGermanyItalyNetherlandsNorwayPolandPortugalSlovakiaSpainUnited Kingdom
  • Understanding biliary tract cancer treatment with rilvegostomig and chemotherapy

    This study focuses on a new treatment for biliary tract cancer using the drug rilvegostomig combined with chemotherapy. It is for patients who have had surgery to remove this cancer. The study will compare the effectiveness of rilvegostomig with a placebo in combination with investigator’s choice of chemotherapy options like capecitabine, gemcitabine/cisplatin, or S-1. The main aim is to see if this new treatment can prevent cancer from coming back. About 750 people will take part in this global study, which is in the final phase of testing.

    BelgiumDenmarkGermanyItalyNorwayPolandSpainUnited Kingdom
  • Research on medicine combination for B-cell Non-Hodgkin Lymphoma

    This study is about testing epcoritamab, a new drug for a type of blood cancer called B-cell Non-Hodgkin Lymphoma. The goal is to see if the drug is safe for people and can successfully fight the cancer. Doctors will combine this drug with other medicines that are typically used to treat this cancer. The combined treatment will vary for different groups of patients, depending on factors like their specific type of cancer or their overall health. Some patients will be given epcoritamab on its own, while others will receive it with other cancer medicines. The study has two parts. The first part is to find a safe dose of the drug. The second part is to determine how well this drug helps in treating the cancer. Side effects will be closely monitored during the study.

    BelgiumCzechiaDenmarkFinlandFranceItalyNetherlandsNorwaySpainSwedenUnited Kingdom
  • Trial on new immune therapies for advanced liver and bile duct cancer

    This study is for people with advanced cancers in the liver and biliary system. The main purpose of the study is to test the effectiveness and safety of new drugs that work with the body’s immune system. These drugs can be used by themselves or with other anti-cancer drugs. The study is separated into two parts. In the first part, around 120 participants with advanced liver cancer will be given MEDI5752 (volrustomig) by itself or with bevacizumab or lenvatinib. The second part involves about 60 participants with advanced bile duct cancer (that haven’t been treated) who will be given AZD2936 or MEDI5752 along with gemcitabine and cisplatin.

    ItalySpainUnited Kingdom
  • Exploring treatment options for newly diagnosed Multiple Myeloma

    This clinical trial investigates two treatment paths for newly diagnosed multiple myeloma patients who are not planned for stem cell transplant initially. The first group receives a combination of bortezomib, lenalidomide, and dexamethasone (VRd) followed by cilta-cel, an innovative therapy. The second group receives VRd followed by continued treatment with lenalidomide and dexamethasone (Rd). The study evaluates the effectiveness of these treatments by monitoring disease progression, treatment response, and patient survival rates. It also assesses the safety and side effects of the treatments, aiming to improve the quality of life and outcomes for patients with multiple myeloma. The trial’s objective is to provide valuable data on the potential benefits of integrating cilta-cel in the treatment regimen, compared to the more traditional approach, offering insights for better management of this challenging cancer.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryNetherlandsNorwayPolandSwedenUnited Kingdom
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    BelgiumFinlandFranceGermanyGreeceItalyNetherlandsNorwayPortugalSpainSwedenUnited Kingdom

See more clinical trials in other cities in United Kingdom:

.